WO2003087367A3 - Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye - Google Patents
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye Download PDFInfo
- Publication number
- WO2003087367A3 WO2003087367A3 PCT/EP2003/004002 EP0304002W WO03087367A3 WO 2003087367 A3 WO2003087367 A3 WO 2003087367A3 EP 0304002 W EP0304002 W EP 0304002W WO 03087367 A3 WO03087367 A3 WO 03087367A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cns
- eye
- tissue
- methods
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 230000004378 blood-retinal barrier Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003584308A JP5578388B2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for specific inhibition of genes in the central nervous system and / or cells and tissues of the eye |
US10/511,656 US20050222061A1 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
AU2003224087A AU2003224087B2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the CNS and/or eye |
MXPA04010282A MXPA04010282A (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye. |
EP03720485A EP1495121A2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
CA002482903A CA2482903A1 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US12/828,624 US20110021605A1 (en) | 2002-04-18 | 2010-07-01 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02008761 | 2002-04-18 | ||
EP02008761.5 | 2002-04-18 | ||
US43117302P | 2002-12-05 | 2002-12-05 | |
US60/431,173 | 2002-12-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/828,624 Continuation US20110021605A1 (en) | 2002-04-18 | 2010-07-01 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003087367A2 WO2003087367A2 (en) | 2003-10-23 |
WO2003087367A3 true WO2003087367A3 (en) | 2004-04-29 |
Family
ID=47711411
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004002 WO2003087367A2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
PCT/EP2003/004003 WO2003087368A2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004003 WO2003087368A2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
Country Status (9)
Country | Link |
---|---|
US (5) | US8202845B2 (en) |
EP (2) | EP1495121A2 (en) |
JP (2) | JP5578388B2 (en) |
AU (3) | AU2003222820A1 (en) |
CA (2) | CA2482904A1 (en) |
ES (1) | ES2397060T3 (en) |
HK (1) | HK1072074A1 (en) |
MX (2) | MXPA04010283A (en) |
WO (2) | WO2003087367A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1708575A4 (en) * | 2004-01-23 | 2009-07-01 | Advanced Cell Tech Inc | Improved modalities for the treatment of degenerative diseases of the retina |
US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
GB0418762D0 (en) * | 2004-08-23 | 2004-09-22 | Genomica Sau | Methods and compositions to treat glaucoma |
CN105251024A (en) * | 2004-08-23 | 2016-01-20 | 西伦蒂斯私人股份公司 | Treatment of eye disorders |
TW200639253A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
JP2009540011A (en) * | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. | Compositions and methods for siRNA inhibition of angiogenesis |
HUE037173T2 (en) | 2006-08-08 | 2018-08-28 | Univ Bonn Rheinische Friedrich Wilhelms | Structure and use of 5' phosphate oligonucleotides |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
JP2010507387A (en) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
CN103898110A (en) | 2007-10-03 | 2014-07-02 | 夸克制药公司 | Novel sirna structures |
CN101878295A (en) | 2007-10-12 | 2010-11-03 | 先进细胞技术公司 | Improved methods of producing RPE cells and compositions of RPE cells |
EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
AU2009322279A1 (en) | 2008-12-04 | 2011-07-14 | Opko Pharmaceuticals, Llc | Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
EP2862929B1 (en) * | 2009-12-09 | 2017-09-06 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating diseases, disorders or injury of the CNS |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
CN103403184A (en) * | 2010-12-23 | 2013-11-20 | 劳伦特·亚历山大 | Method to obtain optical means adapted to a human individual suffering or susceptible to suffer from one or more genetic related eye disorder(s) or disease(s) |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
WO2012151324A1 (en) * | 2011-05-02 | 2012-11-08 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
ES2750125T3 (en) | 2012-09-05 | 2020-03-25 | Sylentis Sau | SiRNA and its use in methods and compositions for the treatment and / or prevention of eye conditions |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10061111B2 (en) | 2014-01-17 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems and methods for three dimensional imaging |
JP7180964B2 (en) * | 2014-01-17 | 2022-11-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Three-dimensional imaging apparatus and method |
WO2015132303A1 (en) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
KR102506169B1 (en) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
KR20170095417A (en) * | 2016-02-11 | 2017-08-23 | 삼성전자주식회사 | Lighting device and electronic device including the same |
US10835111B2 (en) | 2016-07-10 | 2020-11-17 | The Trustees Of Columbia University In The City Of New York | Three-dimensional imaging using swept, confocally aligned planar excitation with an image relay |
US10712545B2 (en) * | 2017-03-07 | 2020-07-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Systems and methods for conducting contact-free thickness and refractive-index measurements of intraocular lenses using a self-calibrating dual confocal microscopy system |
CN108739556A (en) * | 2018-08-31 | 2018-11-06 | 南京工业大学 | A kind of application of photochemical induction zebra fish cerebral arterial thrombosis model |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308066A2 (en) * | 1987-08-12 | 1989-03-22 | Hem Pharmaceuticals Corp. | Promotion of host defense by systemic dsRNA treatment |
WO1997020579A2 (en) * | 1995-12-05 | 1997-06-12 | Smithkline Beecham Plc | Novel compounds and use |
WO1998022132A1 (en) * | 1996-11-20 | 1998-05-28 | Yissum Res Dev Co | A method and composition for enabling passage through the blood-brain barrier |
WO2000044914A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2001083729A2 (en) * | 2000-05-01 | 2001-11-08 | Novartis Ag | Vectors for ocular transduction and use thereof for genetic therapy |
WO2001082900A1 (en) * | 2000-04-25 | 2001-11-08 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5545412A (en) * | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
US5498521A (en) * | 1990-01-24 | 1996-03-12 | President And Fellows Of Harvard College | Diagnosis of hereditary retinal degenerative diseases |
US5843738A (en) * | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
EP0669987B1 (en) | 1992-09-25 | 2008-08-13 | Aventis Pharma S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
EP0769552A4 (en) * | 1994-06-27 | 1997-06-18 | Toagosei Co Ltd | Antisense nucleic acid compound |
US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US20030216335A1 (en) * | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
WO1997018855A1 (en) | 1995-11-21 | 1997-05-29 | Eduard Naumovich Lerner | Device for enhanced delivery of biologically active substances and compounds in an organism |
US5843016A (en) * | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
US7033598B2 (en) * | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
AU735788B2 (en) | 1997-04-21 | 2001-07-12 | University Of Florida | Materials and methods for ribozyme treatment of diseases |
US20050096282A1 (en) * | 1997-04-21 | 2005-05-05 | Lewin Alfred S. | Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases |
CA2295177C (en) * | 1997-06-13 | 2007-01-09 | Medinova Medical Consulting Gmbh | Drug targeting system, method of its preparation and its use |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6440933B1 (en) | 1997-09-10 | 2002-08-27 | University Of Florida | Compounds and method for the prevention and treatment of diabetic retinopathy |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US20030096775A1 (en) | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
US6433145B1 (en) * | 1998-07-21 | 2002-08-13 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
EP0979869A1 (en) * | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US6219557B1 (en) * | 1998-12-11 | 2001-04-17 | Ericsson Inc. | System and method for providing location services in parallel to existing services in general packet radio services architecture |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
CA2361421A1 (en) * | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6121000A (en) * | 1999-02-11 | 2000-09-19 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
EP2339006A3 (en) * | 1999-12-16 | 2011-10-19 | Monsanto Technology LLC | Dna constructs for expression of heterologous polypeptides in plants |
CN101053573A (en) | 2000-01-19 | 2007-10-17 | 帕卡什·S·吉尔 | Compositions and methods based on VEGF antisense oligonucleotides |
AU3974001A (en) | 2000-02-03 | 2001-08-14 | Ali R. Fattaey | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
IL153525A0 (en) * | 2000-06-23 | 2003-07-06 | Yissum Res Dev Co | Positively-charged peptide nucleic acid analogs with improved properties |
AU2001271614B2 (en) * | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
CA2416676A1 (en) * | 2000-07-21 | 2002-01-31 | The Trustees Of Columbia University In The City Of New York | Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
IL137672A0 (en) | 2000-08-03 | 2001-10-31 | Dpharm Ltd | Derivatives of branched-chain lipophilic molecules and uses thereof |
US6443145B1 (en) * | 2000-08-25 | 2002-09-03 | Learning Legacy | Solar seeker |
US20020132788A1 (en) * | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
EP1873259B1 (en) * | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
CA2369944A1 (en) | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
JP2002305193A (en) * | 2001-04-05 | 2002-10-18 | Sony Corp | Semiconductor device and method of manufacturing the same |
US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
JP2005500025A (en) | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | Nucleic acid-based regulation of female reproductive diseases and conditions |
EP1401884A1 (en) | 2001-05-29 | 2004-03-31 | Union Carbide Chemicals & Plastics Technology Corporation | Olefin polymerization catalyst compositions and method of preperation |
DK2280070T3 (en) * | 2001-07-23 | 2015-08-24 | Univ Leland Stanford Junior | Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals |
ATE462006T1 (en) | 2001-08-01 | 2010-04-15 | Univ Bristol | ISOFORM OF VEGF |
WO2003040399A2 (en) * | 2001-11-02 | 2003-05-15 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
WO2003046173A1 (en) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME |
ES2649817T3 (en) * | 2002-04-05 | 2018-01-15 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for modulation of the expression of HIF-1¿Á |
WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
AU2003237686A1 (en) | 2002-05-24 | 2003-12-12 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US20040115640A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of angiopoietin-2 expression |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2003258100A1 (en) | 2002-08-06 | 2004-02-23 | Intradigm Corporation | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
US7521431B2 (en) * | 2002-11-01 | 2009-04-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
EP2284266B1 (en) * | 2002-11-14 | 2013-11-06 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting tp53 |
ATE477337T1 (en) * | 2003-01-16 | 2010-08-15 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1 |
MXPA05011221A (en) * | 2003-04-18 | 2006-02-17 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2. |
US20050019927A1 (en) * | 2003-07-13 | 2005-01-27 | Markus Hildinger | DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
JP4937899B2 (en) * | 2004-03-12 | 2012-05-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | IRNA substances targeting VEGF |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
TWI243957B (en) * | 2004-08-16 | 2005-11-21 | Asia Optical Co Inc | Assembling method of reticle module |
KR20080041145A (en) | 2005-04-12 | 2008-05-09 | 인트라디그엠 코오포레이션 | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
NZ569368A (en) * | 2005-12-22 | 2011-11-25 | Exegenics Inc D B A Opko Health Inc | siRNA compositions and methods for regulating the C3 protein in the complement system |
EP1982176A1 (en) * | 2006-01-30 | 2008-10-22 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
JP2009540011A (en) | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. | Compositions and methods for siRNA inhibition of angiogenesis |
US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
-
2003
- 2003-04-16 WO PCT/EP2003/004002 patent/WO2003087367A2/en active Application Filing
- 2003-04-16 US US10/511,657 patent/US8202845B2/en not_active Expired - Lifetime
- 2003-04-16 JP JP2003584308A patent/JP5578388B2/en not_active Expired - Fee Related
- 2003-04-16 CA CA002482904A patent/CA2482904A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010283A patent/MXPA04010283A/en not_active Application Discontinuation
- 2003-04-16 EP EP03720485A patent/EP1495121A2/en not_active Ceased
- 2003-04-16 EP EP03718764A patent/EP1495120B1/en not_active Expired - Lifetime
- 2003-04-16 CA CA002482903A patent/CA2482903A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010282A patent/MXPA04010282A/en not_active Application Discontinuation
- 2003-04-16 AU AU2003222820A patent/AU2003222820A1/en not_active Abandoned
- 2003-04-16 US US10/511,656 patent/US20050222061A1/en not_active Abandoned
- 2003-04-16 JP JP2003584309A patent/JP2006500910A/en active Pending
- 2003-04-16 ES ES03718764T patent/ES2397060T3/en not_active Expired - Lifetime
- 2003-04-16 WO PCT/EP2003/004003 patent/WO2003087368A2/en active Application Filing
- 2003-04-16 AU AU2003224087A patent/AU2003224087B2/en not_active Ceased
-
2005
- 2005-06-08 HK HK05104837.4A patent/HK1072074A1/en unknown
-
2009
- 2009-02-23 AU AU2009200699A patent/AU2009200699A1/en not_active Abandoned
-
2010
- 2010-07-01 US US12/828,624 patent/US20110021605A1/en not_active Abandoned
-
2012
- 2012-06-11 US US13/493,690 patent/US8946180B2/en not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/577,251 patent/US20150105448A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308066A2 (en) * | 1987-08-12 | 1989-03-22 | Hem Pharmaceuticals Corp. | Promotion of host defense by systemic dsRNA treatment |
WO1997020579A2 (en) * | 1995-12-05 | 1997-06-12 | Smithkline Beecham Plc | Novel compounds and use |
WO1998022132A1 (en) * | 1996-11-20 | 1998-05-28 | Yissum Res Dev Co | A method and composition for enabling passage through the blood-brain barrier |
WO2000044914A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2001082900A1 (en) * | 2000-04-25 | 2001-11-08 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
WO2001083729A2 (en) * | 2000-05-01 | 2001-11-08 | Novartis Ag | Vectors for ocular transduction and use thereof for genetic therapy |
Non-Patent Citations (5)
Title |
---|
CARLSON S.D. AND HILGERS S.L.: "Perineurium in the Drosophila (Diptera: Drosophilidae) embryo and its role in the blood-brain/nerve barrier", INTERNATIONAL JOURNAL OF INSECT MORPHOLOGY AND EMBRYOLOGY, vol. 27, no. 2, April 1998 (1998-04-01), pages 61 - 66, XP002259381 * |
DZITOYEVA S. ET AL.: "Intra-abdominal injection of double-stranded RNA into anesthetized adult Drosophila triggers RNA interference in the central nervous system", MOLECULAR PSYCHIATRY, vol. 6, no. 6, November 2001 (2001-11-01), pages 665 - 670, XP008023738 * |
GAN L. ET AL.: "Specific interference of gene function by double-stranded RNA in neuronal cell lines", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, pages 2051, XP002259262 * |
LAWSON S.S. AND JOHNSON C.: "Understanding the Glaucoma gene", MOLECULAR BIOLOGY OF THE CELL. 40TH AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING; SAN FRANCISCO, CA, USA; DECEMBER 9-13, 2000, vol. 11, no. supplement, December 2000 (2000-12-01), pages 14a, XP008023805 * |
PINEDA D. ET AL.: "The genetic network of prototypic planarian eye regeneration is Pax6 independent", DEVELOPMENT, vol. 129, March 2002 (2002-03-01), pages 1423 - 1434, XP002259263 * |
Also Published As
Publication number | Publication date |
---|---|
US20110021605A1 (en) | 2011-01-27 |
US20150105448A1 (en) | 2015-04-16 |
CA2482904A1 (en) | 2003-10-23 |
AU2003222820A1 (en) | 2003-10-27 |
MXPA04010282A (en) | 2005-08-18 |
JP2005538940A (en) | 2005-12-22 |
WO2003087368A2 (en) | 2003-10-23 |
WO2003087367A2 (en) | 2003-10-23 |
AU2003224087A1 (en) | 2003-10-27 |
AU2003224087B2 (en) | 2009-03-05 |
AU2009200699A1 (en) | 2009-03-12 |
CA2482903A1 (en) | 2003-10-23 |
US8202845B2 (en) | 2012-06-19 |
ES2397060T3 (en) | 2013-03-04 |
US20120277288A1 (en) | 2012-11-01 |
EP1495121A2 (en) | 2005-01-12 |
JP5578388B2 (en) | 2014-08-27 |
HK1072074A1 (en) | 2005-08-12 |
EP1495120A2 (en) | 2005-01-12 |
EP1495120B1 (en) | 2012-10-10 |
US20060003915A1 (en) | 2006-01-05 |
WO2003087368A3 (en) | 2004-04-29 |
JP2006500910A (en) | 2006-01-12 |
US8946180B2 (en) | 2015-02-03 |
MXPA04010283A (en) | 2005-08-18 |
US20050222061A1 (en) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003087367A3 (en) | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye | |
WO2005078097A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) | |
WO2005005601A8 (en) | Compositions and methods for treating and diagnosing cancer | |
WO2005019453A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2005019418A3 (en) | Modulation of diacylglycerol acyltransferase 2 expression | |
EP3926046A3 (en) | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) | |
ATE354957T1 (en) | THERAPEUTIC MOLECULES OBTAINED BY TRANS-CLIPATION | |
WO2006084209A3 (en) | Rnai expression constructs | |
WO2004111273A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
WO2006138275A3 (en) | Compositions and methods for treating and diagnosing cancer | |
WO2005082341A3 (en) | NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF | |
WO2007072220A3 (en) | Focused microarray and methods of diagnosing cancer | |
WO2010022166A3 (en) | Micro rna and neurofibromatosis type 1 in diagnosis and therapy | |
WO2005113831A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
WO2001084148A3 (en) | Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions | |
AU2003220115A1 (en) | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues | |
WO2004055162A3 (en) | Modulation of endothelial lipase expression | |
PL1857555T3 (en) | Method for the production of a cell and/or tissue disease phase specific treatment | |
WO2003070887A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2004048522A3 (en) | Modulation of huntingtin interacting protein 2 expression | |
WO2005042552A3 (en) | Modulation of sglt2 expression | |
WO2002101071A3 (en) | Cd43:modulators of mast cell degranulation | |
WO2004043394A3 (en) | Modulation of huntingtin interacting protein 1 expression | |
WO2005001031A3 (en) | Modulation of the rna interference pathway | |
WO2000017346A3 (en) | Hairpin hybridizer molecules for modulation of gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/010282 Country of ref document: MX Ref document number: 2482903 Country of ref document: CA Ref document number: 2003584308 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003224087 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003720485 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003720485 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10511656 Country of ref document: US |